This opens up a promising avenue for therapeutic intervention by designing ASOs that specifically target the RBM20 binding sites on TTN pre-mRNA to reduce diastolic stiffness in patients with heart failure with HFpEF and DCM. The gene discussed is RBM20; the disease is heart failure.